Search the Newsreel

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

RenovoRx announced record financial results for the second quarter of 2026, with revenue reaching $909,000, marking a 61% sequential quarterly increase and a 115% year-over-year increase. The company raised its 2026 annual revenue guidance to a range of $3.75 million to $4.25 million, driven …

RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS

RenovoRx (NASDAQ:RNXT) reported a narrower-than-expected quarterly loss of $0.05 per share, surpassing consensus estimates by $0.02. The company also saw significant revenue growth, climbing 61% sequentially and 115% year-over-year to $909,000, leading management to raise its 2026 revenue guidance. Despite this progress, RenovoRx remains …

Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance

RenovoRx announced a strong Q2 2026 performance, exceeding Wall Street expectations with higher-than-forecasted revenue of $909,000 and a smaller loss of 6 cents per share. The medical device company raised its full-year 2026 revenue guidance to $3.75 million to $4.25 million, citing record quarterly …

RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...

RenovoRx Inc (RNXT) reported record Q2 2026 revenue of $909,000, a 61% sequential and 115% year-over-year increase, driven by an expanded commercial presence in cancer centers. The company also announced full enrollment for its Phase 3 TIGERPAC trial, with top-line data expected in late …

RenovoRx completes enrollment in phase III pancreatic cancer trial

RenovoRx (NASDAQ:RNXT) has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, with patient enrollment closing on August 7th. The company anticipates trial completion by the first half of 2027, with initial topline data expected in the second half of …

RenovoRx pancreatic cancer trial closes enrollment; 78 deaths occurred

RenovoRx announced the full enrollment of its Phase III

EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027

RenovoRx, Inc. (NASDAQ: RNXT) has completed patient enrollment for its Phase 3 TIGeR-PaC study for locally advanced pancreatic cancer (LAPC), utilizing its RenovoCath targeted drug delivery platform. The study, which compares intra-arterial gemcitabine (IAG) against standard systemic chemotherapy, is expected to conclude in the …

Earnings Preview: RenovoRx to Report Financial Results Post-market on August 12

This article announces that RenovoRx (RNXT) is scheduled to report its financial results after the market closes on August 12, 2026. This preview details the expected date for the release of their earnings report.

RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for RenovoRx Inc (RNXT), noting its current earnings forecast score of 8.00 and an average price target of $3.50 based on 4 analysts. It details expected future EPS and revenue figures, and summarizes analyst sentiment as predominantly "Buy".

RenovoRx Inc (RNXT) Stock News Today

RenovoRx’s RenovoCath used in sarcoma treatment for first time By Investing.com

RenovoRx Inc. announced that its RenovoCath drug-delivery device was used commercially for the first time to treat a sarcoma patient at CARTI Cancer Center. This marks an expansion beyond the company's prior focus on pancreatic cancer, demonstrating the device's potential for local chemotherapy delivery …

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

RenovoRx, Inc. announced the first commercial clinical use of its FDA-cleared RenovoCath device for drug delivery in treating a sarcoma patient at the CARTI Cancer Center. This milestone demonstrates the potential for RenovoCath to expand beyond pancreatic cancer to other solid tumors for localized …

A Sarcoma Patient Is Receiving Local Chemotherapy via RenovoCath

RenovoRx (Nasdaq: RNXT) announced the first commercial clinical use of its RenovoCath device for localized chemotherapy delivery in a sarcoma patient at CARTI Cancer Center. This marks an expansion of the device's application beyond pancreatic cancer, demonstrating its potential for treating other solid tumors …

RenovoRx to Present TAMP Platform, TIGeR-PaC Trial Update at JonesTrading Webinar Aug 13

RenovoRx will present its TAMP platform and provide an update on the TIGeR-PaC trial at a JonesTrading webinar on August 13. CEO Shaun Bagai and oncology KOLs will discuss the RenovoCath and the company's commercial progress, including sales figures and growth plans. The webinar …

RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic?

Analysts are optimistic about RenovoRx, Inc.'s path to profitability, with consensus suggesting the clinical-stage biopharmaceutical company will break even by 2028, generating positive profits of US$5.7 million. This projection relies on an aggressive annual growth rate of 73%. A key positive for the company …

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

RenovoRx, Inc. (Nasdaq: RNXT) announced its participation in a JonesTrading webinar on August 13, 2026, focusing on the evolving pancreatic cancer treatment landscape. CEO Shaun Bagai will discuss the company's Trans-Arterial Micro-Perfusion (TAMP) platform and RenovoCath device, including their potential in delivering targeted chemotherapy …

RenovoRx Webinar to Explore Local Chemotherapy for Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced it will participate in a virtual Key Opinion Leader (KOL) webinar with JonesTrading on August 13, 2026, at 1:30 p.m. ET. The webinar, titled “The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx's TAMP Platform and Emerging Clinical Advances,” will …

RNXT|RenovoRx Inc|Price:1.040|Chg%:+0.082

RenovoRx Inc (RNXT) has a "relatively very healthy" fundamental outlook and high growth potential, with its valuation considered "fairly valued" within the Healthcare Equipment & Supplies industry. Institutional ownership is high, and analysts have rated the stock as a "Buy" with a target price …

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), RenovoRx (RNXT) and ACADIA Pharmaceuticals (ACAD)

Three healthcare companies, Cytokinetics (CYTK), RenovoRx (RNXT), and ACADIA Pharmaceuticals (ACAD), have received bullish sentiments from analysts. Needham maintained a Buy rating for Cytokinetics with a $102 price target, JonesTrading maintained a Buy rating for RenovoRx with an $8 price target, and H.C. Wainwright …

RenovoRx Inc (RNXT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of RenovoRx Inc (RNXT), focusing on its current stock price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 31, 2026, RNXT shows a price momentum score of 3.94, trading between a …

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

RenovoRx, Inc. announced it will host a conference call on August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results and business highlights. Management will cover growing revenues from RenovoCath sales, its adoption in cancer centers, and updates on …

RenovoRx Expects Full Enrollment Soon in Pancreatic Cancer Trial

RenovoRx (RNXT) announced it will host its Q2 2026 financial results and business highlights conference call on August 12, 2026, at 4:30 p.m. ET. The company plans to discuss growing revenues from RenovoCath sales and provide an update on its Phase III TIGeR-PaC trial …

RenovoRx Inc (RNXT) Financial Health: Profitability & Balance Sheet Analysis

RenovoRx Inc (RNXT) currently holds a robust financial score of 7.63, ranking 73rd in the Healthcare Equipment & Supplies industry, despite having low operating efficiency. The company reported a significant year-over-year revenue increase of 185.79% to $563.00K and a 45.50% increase in net profit. …

RenovoRx Inc (RNXT) Institutional Confidence

RenovoRx Inc (RNXT) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. Institutional investors hold 20.02% of the shares, a slight decrease of 0.19% quarter-over-quarter. James Simons is the largest institutional shareholder, with …

RenovoRx Inc (RNXT) Income Statement

This article provides the quarterly and annual income statements for RenovoRx Inc (RNXT), detailing financial performance metrics such as total revenue, operating expenses, operating profit, and net income. It also includes FAQs explaining how to interpret the income statement and highlights key financial figures …

RNXT|RenovoRx Inc|Price:0.959|Chg%:+0.093

RenovoRx, Inc. is a clinical and commercial biopharmaceutical company focused on oncology. Their primary product, RenovoCath, is a local drug delivery device, and they are evaluating a novel Phase III drug-device combination (intra-arterial gemcitabine, IAG) for pancreatic cancer. The article provides company details, executive …

RenovoRx Inc (RNXT) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides dividend and stock split information for RenovoRx Inc (RNXT), noting that the company has not distributed any dividends over the past five years. It shows a market capitalization of $42.36 million and the stock price performance at the time of publication. …

RenovoRx Inc (RNXT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of RenovoRx Inc (RNXT), listing major individual and institutional holders and their respective proportions. It also breaks down shareholder types, including private equity, investment advisors, and individual investors, and provides a quarterly overview of institutional shareholding changes.

RenovoRx, Inc. Revenue Breakdown – NASDAQ:RNXT

RenovoRx, Inc. (NASDAQ: RNXT) generated $1.12 million USD last year, primarily from its Oncology Therapies segment, which accounted for the entire sum. The United States was the sole geographic contributor to this revenue, also totaling $1.12 million. This indicates a significant increase from the …

TradingKey

This article provides a detailed cash flow statement for RenovoRx Inc (RNXT), breaking down operating, investing, and financing cash flows both quarterly and annually. It also includes frequently asked questions about different types of cash flow, such as operating, investing, financing, and free cash …

RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis

RenovoRx Inc (RNXT) currently has a valuation score of 6.01, placing it 189th out of 200 in the Healthcare Equipment & Supplies industry. Its P/E ratio is -2.61, which is significantly lower than its recent high but higher than its recent low. Key valuation …

RenovoRx, Inc. (RNXT) reports Q1 loss, tops revenue estimates

RenovoRx, Inc. (RNXT) announced its first-quarter results, reporting a loss that was narrower than anticipates and revenue that exceeded analyst expectations. The company posted a net loss per share of $0.09 on total revenue of $0.18 million, beating the consensus estimate of a $0.10 …